Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group

BACKGROUND: Erwinia asparaginase is a Food and Drug Administration approved agent for the treatment of acute lymphoblastic leukemia (ALL) for patients who develop hypersensitivity to Escherichia coli derived asparaginases. Erwinia asparaginase is efficacious, but has a short half-life, requiring six...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Pediatr Blood Cancer
Asıl Yazarlar: Rau, Rachel E., Dreyer, ZoAnn, Choi, Mi Rim, Liang, Wei, Skowronski, Roman, Allamneni, Krishna P., Devidas, Meenakshi, Raetz, Elizabeth A., Adamson, Peter C., Blaney, Susan M., Loh, Mignon L, Hunger, Stephen P.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2017
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5839116/
https://ncbi.nlm.nih.gov/pubmed/29090524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.26873
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller